Collegium Pharmaceutical Stock Price, News & Analysis (NASDAQ:COLL)

$24.50 +0.59 (+2.47 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$24.50
Today's Range$22.61 - $24.66
52-Week Range$7.37 - $26.77
Volume400,763 shs
Average Volume634,434 shs
Market Capitalization$797.78 million
P/E Ratio-8.25
Dividend YieldN/A
BetaN/A

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical logoCollegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:COLL
CUSIPN/A
Phone+1-781-7133699

Debt

Debt-to-Equity RatioN/A
Current Ratio4.51%
Quick Ratio4.45%

Price-To-Earnings

Trailing P/E Ratio-8.24915824915825
Forward P/E Ratio-9.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.71 million
Price / Sales466.50
Cash FlowN/A
Price / CashN/A
Book Value$4.72 per share
Price / Book5.19

Profitability

Trailing EPS($2.97)
Net Income$-94,170,000.00
Net Margins-447.83%
Return on Equity-77.11%
Return on Assets-61.94%

Miscellaneous

Employees234
Outstanding Shares32,560,000

Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.73) by $0.28. The specialty pharmaceutical company had revenue of $11.95 million for the quarter, compared to analyst estimates of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm's revenue for the quarter was up 2814.6% on a year-over-year basis. During the same quarter last year, the business posted ($1.13) EPS. View Collegium Pharmaceutical's Earnings History.

When will Collegium Pharmaceutical make its next earnings announcement?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Collegium Pharmaceutical.

Where is Collegium Pharmaceutical's stock going? Where will Collegium Pharmaceutical's stock price be in 2018?

5 equities research analysts have issued 12 month price targets for Collegium Pharmaceutical's shares. Their predictions range from $21.00 to $35.00. On average, they expect Collegium Pharmaceutical's share price to reach $29.40 in the next year. View Analyst Ratings for Collegium Pharmaceutical.

Who are some of Collegium Pharmaceutical's key competitors?

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:

  • Michael Thomas Heffernan, Chairman of the Board, President, Chief Executive Officer (Age 52)
  • Paul Brannelly CPA, Chief Financial Officer, Executive Vice President (Age 42)
  • Joseph J. Ciaffoni, Chief Operating Officer, Executive Vice President
  • Douglas R. Carlson, Vice President - Corporate Development
  • Alison B Fleming, Vice President of Product Development (Age 40)
  • Ernest A. Kopecky Ph.D., Vice President - Clinical Development and Head of Neuroscience (Age 48)
  • Kevin OKeeffe, Vice President - Market Access and Trade
  • Steven Passik Ph.D., Vice President - Scientific Affairs, Education and Policy
  • Said Saim Ph.D., Vice President of Pharmaceutical Development (Age 57)
  • John Weet Ph.D., Vice President - Regulatory Affairs and Quality Assurance

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who owns Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.04%), Rock Springs Capital Management LP (5.79%), Macquarie Group Ltd. (4.96%), Franklin Resources Inc. (4.64%), Sectoral Asset Management Inc (4.38%) and Citadel Advisors LLC (2.64%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, John A Fallon, Longitude Capital Partners, Ll, Michael Thomas Heffernan and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.

Who sold Collegium Pharmaceutical stock? Who is selling Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Franklin Resources Inc., Sectoral Asset Management Inc, Highland Capital Management LP, Brandywine Global Investment Management LLC and Rhumbline Advisers. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Longitude Capital Partners, Ll and Michael Thomas Heffernan. View Insider Buying and Selling for Collegium Pharmaceutical.

Who bought Collegium Pharmaceutical stock? Who is buying Collegium Pharmaceutical stock?

Collegium Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., Deutsche Bank AG, Citadel Advisors LLC, Cortina Asset Management LLC, Macquarie Group Ltd., Rice Hall James & Associates LLC, Nicholas Investment Partners LP and Chartwell Investment Partners LLC. Company insiders that have bought Collegium Pharmaceutical stock in the last two years include John A Fallon and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.

How do I buy Collegium Pharmaceutical stock?

Shares of Collegium Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of Collegium Pharmaceutical stock can currently be purchased for approximately $24.50.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $797.78 million and generates $1.71 million in revenue each year. The specialty pharmaceutical company earns $-94,170,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Collegium Pharmaceutical employs 234 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 780 Dedham St Ste 800, CANTON, MA 02021-1417, United States. The specialty pharmaceutical company can be reached via phone at +1-781-7133699.


MarketBeat Community Rating for Collegium Pharmaceutical (COLL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Collegium Pharmaceutical (NASDAQ:COLL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.40$26.80$20.00$22.20
Price Target Upside: 35.05% upside10.20% upside18.91% upside75.77% upside

Collegium Pharmaceutical (NASDAQ:COLL) Consensus Price Target History

Price Target History for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018Jefferies GroupBoost Price TargetBuy$32.00LowView Rating Details
2/12/2018Piper Jaffray CompaniesSet Price TargetBuy$33.00HighView Rating Details
2/7/2018Needham & Company LLCBoost Price TargetBuy -> Buy$28.00 -> $35.00LowView Rating Details
2/6/2018Janney Montgomery ScottSet Price TargetBuy -> Buy$21.00 -> $26.00LowView Rating Details
11/17/2017HC WainwrightReiterated RatingBuy$21.00N/AView Rating Details
9/13/2016GabelliInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Collegium Pharmaceutical (NASDAQ:COLL) Earnings History and Estimates Chart

Earnings by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ COLL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.56)N/AView Earnings Details
11/8/2017Q3 2017($0.73)($0.45)$5.31 million$11.95 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.81)($0.72)$4.07 million$3.56 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.98)($0.79)$3.55 million$2.17 millionViewN/AView Earnings Details
3/9/2017Q4 2016($1.07)($1.02)$1.79 million$1.30 millionViewListenView Earnings Details
11/10/2016Q3 2016($1.09)($1.13)$1.00 million$0.41 millionViewListenView Earnings Details
8/10/2016Q2($0.76)($1.05)$0.16 millionViewListenView Earnings Details
5/10/2016Q1($0.60)($0.68)ViewListenView Earnings Details
3/15/2016Q415($0.45)($0.46)ViewListenView Earnings Details
11/12/2015Q315($0.30)($0.46)ViewListenView Earnings Details
8/12/2015Q215($0.26)($0.45)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Collegium Pharmaceutical (NASDAQ:COLL) Earnings Estimates

2018 EPS Consensus Estimate: ($1.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.36)($1.36)($1.36)
Q2 20181($0.35)($0.35)($0.35)
Q3 20181($0.17)($0.17)($0.17)
Q4 20181$0.31$0.31$0.31
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Collegium Pharmaceutical (NASDAQ:COLL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Collegium Pharmaceutical (NASDAQ COLL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.76%
Institutional Ownership Percentage: 89.28%
Insider Trades by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)
Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ COLL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2018Michael Thomas HeffernanChairmanSell20,000$25.01$500,200.00535,395View SEC Filing  
1/19/2018Michael Thomas HeffernanChairmanSell20,000$22.50$450,000.00538,987View SEC Filing  
1/10/2018Alison B FlemingInsiderSell6,928$19.07$132,116.9632,651View SEC Filing  
12/8/2017Longitude Capital Partners, LlMajor ShareholderSell1,000,000$17.34$17,340,000.00View SEC Filing  
11/21/2017Alison B FlemingInsiderSell4,601$17.25$79,367.2528,513View SEC Filing  
11/17/2017Alison B FlemingCTOSell4,029$17.00$68,493.0028,513View SEC Filing  
11/15/2017Michael Thomas HeffernanCEOSell50,000$15.53$776,500.00558,987View SEC Filing  
5/12/2017Paul BrannellyInsiderBuy10,000$9.18$91,800.00110,227View SEC Filing  
8/12/2016John A FallonDirectorBuy2,375$10.59$25,151.252,375View SEC Filing  
5/12/2015John Gordon FreundDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
5/12/2015Longitude Capital Partners, LlMajor ShareholderBuy200,000$12.00$2,400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Collegium Pharmaceutical (NASDAQ COLL) News Headlines

Source:
DateHeadline
Comparing Collegium Pharmaceutical (COLL) & Impax Laboratories (IPXL)Comparing Collegium Pharmaceutical (COLL) & Impax Laboratories (IPXL)
www.americanbankingnews.com - February 22 at 12:42 PM
Collegium Pharmaceutical (COLL) Price Target Raised to $35.00Collegium Pharmaceutical (COLL) Price Target Raised to $35.00
www.americanbankingnews.com - February 20 at 12:24 AM
BidaskClub Upgrades Collegium Pharmaceutical (COLL) to "Buy"BidaskClub Upgrades Collegium Pharmaceutical (COLL) to "Buy"
www.americanbankingnews.com - February 17 at 11:36 PM
Collegium Pharmaceutical Inc (COLL) Given Consensus Recommendation of "Buy" by BrokeragesCollegium Pharmaceutical Inc (COLL) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 17 at 9:46 AM
Collegium Pharmaceutical Inc (COLL) Expected to Post Q4 2017 Earnings of ($0.50) Per ShareCollegium Pharmaceutical Inc (COLL) Expected to Post Q4 2017 Earnings of ($0.50) Per Share
www.americanbankingnews.com - February 14 at 6:30 AM
Analysts Offer Predictions for Collegium Pharmaceutical Incs FY2017 Earnings (COLL)Analysts Offer Predictions for Collegium Pharmaceutical Inc's FY2017 Earnings (COLL)
www.americanbankingnews.com - February 14 at 6:08 AM
FY2020 EPS Estimates for Collegium Pharmaceutical Inc Lifted by Jefferies Group (COLL)FY2020 EPS Estimates for Collegium Pharmaceutical Inc Lifted by Jefferies Group (COLL)
www.americanbankingnews.com - February 13 at 4:16 PM
Piper Jaffray Companies Reiterates $33.00 Price Target for Collegium Pharmaceutical (COLL)Piper Jaffray Companies Reiterates $33.00 Price Target for Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - February 12 at 11:52 PM
Jefferies Group Increases Collegium Pharmaceutical (COLL) Price Target to $32.00Jefferies Group Increases Collegium Pharmaceutical (COLL) Price Target to $32.00
www.americanbankingnews.com - February 12 at 10:46 PM
Janney Montgomery Scott Analysts Give Collegium Pharmaceutical (COLL) a $26.00 Price TargetJanney Montgomery Scott Analysts Give Collegium Pharmaceutical (COLL) a $26.00 Price Target
www.americanbankingnews.com - February 6 at 9:28 PM
Collegium Pharmaceutical (COLL) Downgraded by Zacks Investment Research to "Hold"Collegium Pharmaceutical (COLL) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - February 2 at 8:18 PM
Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Akorn, Collegium Pharma, Horizon Pharma, and Ironwood PharmaQuotidian Technical Highlights on Selected Generic Drugs Stocks -- Akorn, Collegium Pharma, Horizon Pharma, and Ironwood Pharma
www.bizjournals.com - February 2 at 7:06 AM
Gabelli Comments on Collegium Pharmaceutical Incs FY2018 Earnings (COLL)Gabelli Comments on Collegium Pharmaceutical Inc's FY2018 Earnings (COLL)
www.americanbankingnews.com - January 31 at 12:34 PM
Collegium Pharmaceutical (COLL) Stock Rating Lowered by BidaskClubCollegium Pharmaceutical (COLL) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 27 at 10:32 AM
Financial Contrast: Collegium Pharmaceutical (COLL) versus Tetraphase Pharmaceuticals (TTPH)Financial Contrast: Collegium Pharmaceutical (COLL) versus Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - January 27 at 8:20 AM
Collegium Pharmaceutical Inc (COLL) Chairman Michael Thomas Heffernan Sells 20,000 SharesCollegium Pharmaceutical Inc (COLL) Chairman Michael Thomas Heffernan Sells 20,000 Shares
www.americanbankingnews.com - January 23 at 9:32 PM
Collegium Pharmaceutical Inc (COLL) Receives Consensus Rating of "Buy" from AnalystsCollegium Pharmaceutical Inc (COLL) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 23 at 8:06 AM
Insider Selling: Collegium Pharmaceutical Inc (COLL) Chairman Sells 20,000 Shares of StockInsider Selling: Collegium Pharmaceutical Inc (COLL) Chairman Sells 20,000 Shares of Stock
www.americanbankingnews.com - January 19 at 9:52 PM
Collegium Pharmaceutical Inc. (COLL) Has Risen To A New High For The YearCollegium Pharmaceutical Inc. (COLL) Has Risen To A New High For The Year
www.nasdaq.com - January 19 at 10:39 AM
3 Top-Ranked Drug Stocks that are Broker Favorites - Nasdaq3 Top-Ranked Drug Stocks that are Broker Favorites - Nasdaq
www.nasdaq.com - January 18 at 4:52 PM
 Brokerages Expect Collegium Pharmaceutical Inc (COLL) Will Announce Quarterly Sales of $10.98 Million Brokerages Expect Collegium Pharmaceutical Inc (COLL) Will Announce Quarterly Sales of $10.98 Million
www.americanbankingnews.com - January 16 at 2:06 AM
Alison B. Fleming Sells 6,928 Shares of Collegium Pharmaceutical Inc (COLL) StockAlison B. Fleming Sells 6,928 Shares of Collegium Pharmaceutical Inc (COLL) Stock
www.americanbankingnews.com - January 12 at 6:58 PM
Opinion: Harry Boxers three health-care stocks to watch today - MarketWatchOpinion: Harry Boxer's three health-care stocks to watch today - MarketWatch
www.marketwatch.com - January 11 at 9:50 AM
Depomed Announces Closing of NUCYNTA Commercialization Agreement With Collegium Pharmaceutical - GlobeNewswire (press release)Depomed Announces Closing of NUCYNTA Commercialization Agreement With Collegium Pharmaceutical - GlobeNewswire (press release)
globenewswire.com - January 11 at 9:50 AM
Collegium Pharmaceutical, Inc. :COLL-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Collegium Pharmaceutical, Inc. :COLL-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 9:29 AM
Zacks: Brokerages Anticipate Collegium Pharmaceutical Inc (COLL) Will Post Quarterly Sales of $10.98 MillionZacks: Brokerages Anticipate Collegium Pharmaceutical Inc (COLL) Will Post Quarterly Sales of $10.98 Million
www.americanbankingnews.com - December 31 at 12:26 PM
Collegium Pharmaceutical (COLL) Raised to Strong-Buy at BidaskClubCollegium Pharmaceutical (COLL) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - December 29 at 11:56 AM
Collegium Pharmaceutical Inc (COLL) Given Average Rating of "Buy" by AnalystsCollegium Pharmaceutical Inc (COLL) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 29 at 8:04 AM
Neos Therapeutics (NEOS) & Collegium Pharmaceutical (COLL) Head to Head ReviewNeos Therapeutics (NEOS) & Collegium Pharmaceutical (COLL) Head to Head Review
www.americanbankingnews.com - December 24 at 7:18 PM
Collegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare ConferenceCollegium to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
finance.yahoo.com - December 21 at 9:30 AM
Piper Jaffray Companies Analysts Give Collegium Pharmaceutical (COLL) a $23.00 Price TargetPiper Jaffray Companies Analysts Give Collegium Pharmaceutical (COLL) a $23.00 Price Target
www.americanbankingnews.com - December 15 at 9:18 PM
North Carolina doctors see jump in opioid-related paymentsNorth Carolina doctors see jump in opioid-related payments
www.bizjournals.com - December 15 at 9:56 AM
Collegium Pharmaceutical, Inc. (COLL) Short Interest UpdateCollegium Pharmaceutical, Inc. (COLL) Short Interest Update
www.americanbankingnews.com - December 15 at 3:08 AM
BioDelivery Sciences Reacquires ONSOLIS® from Collegium PharmaceuticalBioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical
www.nasdaq.com - December 14 at 5:50 PM
Zacks: Brokerages Expect Collegium Pharmaceutical, Inc. (COLL) Will Announce Quarterly Sales of $10.98 MillionZacks: Brokerages Expect Collegium Pharmaceutical, Inc. (COLL) Will Announce Quarterly Sales of $10.98 Million
www.americanbankingnews.com - December 13 at 1:50 AM
Collegium Pharmaceutical, Inc. (COLL) Major Shareholder Sells $17,340,000.00 in StockCollegium Pharmaceutical, Inc. (COLL) Major Shareholder Sells $17,340,000.00 in Stock
www.americanbankingnews.com - December 12 at 5:40 PM
Equities Analysts Set Expectations for Collegium Pharmaceutical, Inc.s FY2018 Earnings (COLL)Equities Analysts Set Expectations for Collegium Pharmaceutical, Inc.'s FY2018 Earnings (COLL)
www.americanbankingnews.com - December 11 at 10:50 AM
Sage Therapeutics Soars: Stock Adds 7.1% in SessionSage Therapeutics Soars: Stock Adds 7.1% in Session
finance.yahoo.com - December 11 at 10:16 AM
Valeant (VRX) in Focus: Stock Moves 11.7% HigherValeant (VRX) in Focus: Stock Moves 11.7% Higher
finance.yahoo.com - December 11 at 10:16 AM
Jefferies Group Weighs in on Collegium Pharmaceutical, Inc.s FY2021 Earnings (COLL)Jefferies Group Weighs in on Collegium Pharmaceutical, Inc.'s FY2021 Earnings (COLL)
www.americanbankingnews.com - December 8 at 8:14 PM
Collegium Pharmaceutical, Inc. (COLL) to Post FY2018 Earnings of ($1.15) Per Share, Gabelli ForecastsCollegium Pharmaceutical, Inc. (COLL) to Post FY2018 Earnings of ($1.15) Per Share, Gabelli Forecasts
www.americanbankingnews.com - December 8 at 1:32 PM
Collegium Pharmaceutical, Inc. (COLL) to Post Q1 2018 Earnings of ($0.81) Per Share, William Blair ForecastsCollegium Pharmaceutical, Inc. (COLL) to Post Q1 2018 Earnings of ($0.81) Per Share, William Blair Forecasts
www.americanbankingnews.com - December 8 at 8:56 AM
Piper Jaffray Companies Reaffirms Buy Rating for Collegium Pharmaceutical (COLL)Piper Jaffray Companies Reaffirms Buy Rating for Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - December 7 at 8:02 AM
East Bay drug maker cuts roster by 40%, looks to move HQ out of stateEast Bay drug maker cuts roster by 40%, looks to move HQ out of state
www.bizjournals.com - December 5 at 5:14 PM
How Two Drugmakers Rocketed On A Deal That Sees One Exit Opioid SalesHow Two Drugmakers Rocketed On A Deal That Sees One Exit Opioid Sales
finance.yahoo.com - December 5 at 5:14 PM
Here's Why Collegium Pharmaceutical Rose as Much as 23.5% TodayHere's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
finance.yahoo.com - December 5 at 5:14 PM
Collegium Pharmaceutical (COLL) PT Raised to $27.00Collegium Pharmaceutical (COLL) PT Raised to $27.00
www.americanbankingnews.com - December 5 at 5:12 PM
Free Research Reports on These Generic Drugs Stocks -- Ironwood ... - PR Newswire (press release)Free Research Reports on These Generic Drugs Stocks -- Ironwood ... - PR Newswire (press release)
www.prnewswire.com - December 5 at 10:14 AM
Depomed (DEPO) Signs NUCYNTA Commercialization Agreement with Collegium Pharmaceutical (COLL) - StreetInsider.comDepomed (DEPO) Signs NUCYNTA Commercialization Agreement with Collegium Pharmaceutical (COLL) - StreetInsider.com
www.streetinsider.com - December 5 at 10:14 AM
Collegium Pharmaceutical (COLL) PT Raised to $28.00 at Needham & Company LLCCollegium Pharmaceutical (COLL) PT Raised to $28.00 at Needham & Company LLC
www.americanbankingnews.com - December 5 at 7:48 AM

SEC Filings

Collegium Pharmaceutical (NASDAQ:COLL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Collegium Pharmaceutical (NASDAQ:COLL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Collegium Pharmaceutical (NASDAQ COLL) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.